Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

61.58 +7.71 (+14.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,431,276
Open 53.99
Bid (Size) 61.25 (1)
Ask (Size) 61.57 (5)
Prev. Close 53.87
Today's Range 53.30 - 61.69
52wk Range 19.83 - 94.45
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. 
Via Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+22.47%
+22.47%
1 Month
+23.41%
+23.41%
3 Month
+41.63%
+41.63%
6 Month
-31.27%
-31.27%
1 Year
+23.68%
+23.68%

More News

Read More
NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc.
Via SBWire
Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
21 Analysts Have This to Say About Apellis Pharmaceuticals
Via Benzinga
Analyst Ratings for Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Apellis Pharmaceuticals Stock Popped Today
Via Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Via Investor's Business Daily
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
Via Investor's Business Daily
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks Mixed Amid Earnings, Consumer Sentiment Data
Via Talk Markets
JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Constellation Brands To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.